drugset / Trial / NCT06033950
A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients With Heart Failure Who Are Intolerant or Not Eligible for Treatment With Steroidal Mineralocorticoid Receptor Antagonists
Phase 3
Recruiting
2600 enrolled
Colorado Prevention Center
Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma · collabSt. Luke's Hospital, Kansas City, Missouri · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Finerenone will be compared to placebo to determine efficacy and safety of treatment in patients with heart failure and reduced ejection fraction (HFrEF) who are intolerant or ineligible to receive treatment with steroidal mineralocorticoid receptor antagonists (sMRA).
Timeline
- Start
- 2024-08-20
- Primary completion
- 2026-08
- Completion
- 2028-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Finerenone | Small molecule | — | Oral |